Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAEL-101 in Mayo Stage IIIa AL Amyloidosis
NCT04512235Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of anselamimab in amyloid light chain amyloidosis, sponsored by Alexion Pharmaceuticals. Started Nov 2020; status: active, not recruiting.
02
Drugs
anselamimab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04512235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04512235.